Novavax Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Novavax şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-31.4%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-31.4%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Novavax, Inc. (NASDAQ:NVAX) Just Reported, And Analysts Assigned A US$16.67 Price Target

Nov 15

Novavax Q3 Earnings Disappoint, But A Turnaround May Be Underway

Nov 13

Novavax, Inc.'s (NASDAQ:NVAX) 35% Dip In Price Shows Sentiment Is Matching Revenues

Nov 01

Novavax Q3 Earnings A Week Away - Time To Accept A New Reality

Oct 31

Novavax's Future Hinges On Sanofi Deal And Upcoming Milestones

Sep 01

Novavax, Inc.'s (NASDAQ:NVAX) Shares Lagging The Industry But So Is The Business

Aug 14

Novavax, Inc. (NASDAQ:NVAX) Surges 206% Yet Its Low P/S Is No Reason For Excitement

May 14

Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 13

Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely

May 07

Novavax: Another Day Older And Deeper In

Mar 02

Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry

Mar 02

Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00

Mar 01

Novavax Q4 Earnings Preview: Settlement With Gavi Doesn't Solve Problems

Feb 23

Investors Don't See Light At End Of Novavax, Inc.'s (NASDAQ:NVAX) Tunnel

Sep 06

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: NVAX şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: NVAX şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Novavax Piyasaya Karşı Temettü Getirisi

NVAX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (NVAX)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.4%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (NVAX) (3 yıla kadar)	0%

Önemli Temettü: NVAX şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, NVAX şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: NVAX şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: NVAX herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Novavax Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Novavax, Inc. (NASDAQ:NVAX) Just Reported, And Analysts Assigned A US$16.67 Price Target

Forecast breakeven date moved forward to 2025

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Novavax Q3 Earnings Disappoint, But A Turnaround May Be Underway

Novavax, Inc. Revises Revenue Guidance for the Full Year 2024

U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

Novavax, Inc.'s (NASDAQ:NVAX) 35% Dip In Price Shows Sentiment Is Matching Revenues

Novavax Q3 Earnings A Week Away - Time To Accept A New Reality

Novavax, Inc Announces Update on Covid-19-Influenza Combination and Stand-Alone Influenza Phase 3 Trial

Forecast breakeven date pushed back to 2026

Novavax, Inc. Updated 2024-2025 Nuvaxovid™ Covid-19 Vaccine Receives Authorization in the EU

Novavax Announces Availability of Updated Covid-19 Vaccine with Emergency Use Authorization from FDA

Novavax Announces That Novavax COVID-19 Vaccine, Adjuvanted Receives Emergency Use Authorization from the U.S. Food and Drug Administration

Novavax's Future Hinges On Sanofi Deal And Upcoming Milestones

Novavax, Inc.'s (NASDAQ:NVAX) Shares Lagging The Industry But So Is The Business

Novavax: Staying Long Despite Coming Up Short In Q2

New minor risk - Profitability

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Forecast breakeven date pushed back to 2025

Novavax, Inc. Revises Revenue Guidance for the Full Year 2024

Novavax, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Price target decreased by 11% to US$19.17

Novavax Ahead Of Q2 Earnings - Picking Apart The Sanofi Deal

Novavax: New Chapter, Questions Remain

Novavax, Inc. Submits Application to U.S. FDA for Updated Protein-Based 2024-2025 Formula COVID-19 Vaccine

Novavax, Inc. Notifies Retirement of Filip Dubovsky as President, Research and Development, Effective as of June 30, 2024

Price target increased by 13% to US$21.60

President of Research & Development recently sold US$384k worth of stock

Consensus revenue estimates increase by 13%

President of Research & Development notifies of intention to sell stock

Novavax, Inc. (NASDAQ:NVAX) Surges 206% Yet Its Low P/S Is No Reason For Excitement

Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

New major risk - Financial position

Novavax, Inc. Revises Revenue Guidance for the Full Year 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Novavax, Inc. to Report Q1, 2024 Results on May 10, 2024

Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely

Novavax, Inc., Annual General Meeting, Jun 13, 2024

Consensus EPS estimates upgraded to US$0.55 loss

New minor risk - Profitability

No longer forecast to breakeven

Consensus EPS estimates upgraded to US$0.80 loss

President of Research & Development exercised options and sold US$14k worth of stock

Consensus estimates of losses per share improve by 28%

Price target decreased by 20% to US$15.40

Novavax: Another Day Older And Deeper In

Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry

Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00

Full year 2023 earnings: EPS and revenues miss analyst expectations

Novavax, Inc. Provides Earnings Guidance for First Quarter and Full Year 2024

Consensus EPS estimates upgraded to US$0.39 loss, revenue downgraded

New minor risk - Share price stability

Novavax Q4 Earnings Preview: Settlement With Gavi Doesn't Solve Problems

Novavax, Inc. to Report Q4, 2023 Results on Feb 28, 2024

CEO & Director exercised options and sold US$171k worth of stock

Price target increased by 15% to US$23.25

Novavax, Inc. Announces The Taiwan Food and Drug Administration Grants Emergency Use Authorization for Nuvaxovid™ XBB.1.5 Dispersion for Injection Covid-19 Vaccine (Recombinant, Adjuvanted) (NVX-CoV2601) for Active Immunization to Prevent Covid-19 in Individuals Aged 12 and Older

Novavax, Inc. Announces Changes to Executive Leadership Team

No longer forecast to breakeven

New major risk - Shareholder dilution

Price target increased by 11% to US$24.50

Novavax, Inc. Provides Earnings Guidance for the First Quarter of 2024

Third quarter 2023 earnings released: US$1.26 loss per share (vs US$2.15 loss in 3Q 2022)

No longer forecast to breakeven

Novavax, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Novavax's Updates Nuvaxovid COVID-19 Vaccine Receives Positive CHMP Opinion in the EU

Forecast to breakeven in 2024

Consensus estimates of losses per share improve by 11%

Forecast to breakeven in 2024

Novavax Receives Full Marketing Authorization for Prototype COVID-19 Vaccine Nuvaxovid™ in United Kingdom

Investors Don't See Light At End Of Novavax, Inc.'s (NASDAQ:NVAX) Tunnel

Novavax, Inc. Announces Updated Protein-Based XBB Covid Vaccine Induced Neutralizing Responses Against Emerging Subvariants

Consensus EPS estimates fall by 12%

Consensus EPS estimates fall by 12%

Novavax, Inc. announced that it expects to receive $84.5 million in funding from SK bioscience Co.,Ltd.